Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
4,483
archived clinical trials in
Influenza

Study of Menactra® in Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age
An Immunogenicity and Safety Evaluation of Menactra® (Meningococcal [Groups A, C, Y and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine) When Administered to Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age.
Status: Enrolling
Updated:  11/10/2015
Clinical Research Facility
mi
from
Erie, PA
Study of Menactra® in Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age
An Immunogenicity and Safety Evaluation of Menactra® (Meningococcal [Groups A, C, Y and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine) When Administered to Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age.
Status: Enrolling
Updated: 11/10/2015
Clinical Research Facility
mi
from
Erie, PA
Click here to add this to my saved trials
Study of Menactra® in Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age
An Immunogenicity and Safety Evaluation of Menactra® (Meningococcal [Groups A, C, Y and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine) When Administered to Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age.
Status: Enrolling
Updated:  11/10/2015
Clinical Research Facility
mi
from
Harleysville, PA
Study of Menactra® in Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age
An Immunogenicity and Safety Evaluation of Menactra® (Meningococcal [Groups A, C, Y and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine) When Administered to Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age.
Status: Enrolling
Updated: 11/10/2015
Clinical Research Facility
mi
from
Harleysville, PA
Click here to add this to my saved trials
Study of Menactra® in Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age
An Immunogenicity and Safety Evaluation of Menactra® (Meningococcal [Groups A, C, Y and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine) When Administered to Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age.
Status: Enrolling
Updated:  11/10/2015
Clinical Research Facility
mi
from
Hermitage, PA
Study of Menactra® in Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age
An Immunogenicity and Safety Evaluation of Menactra® (Meningococcal [Groups A, C, Y and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine) When Administered to Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age.
Status: Enrolling
Updated: 11/10/2015
Clinical Research Facility
mi
from
Hermitage, PA
Click here to add this to my saved trials
Study of Menactra® in Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age
An Immunogenicity and Safety Evaluation of Menactra® (Meningococcal [Groups A, C, Y and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine) When Administered to Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age.
Status: Enrolling
Updated:  11/10/2015
Clinical Research Facility
mi
from
Scranton, PA
Study of Menactra® in Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age
An Immunogenicity and Safety Evaluation of Menactra® (Meningococcal [Groups A, C, Y and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine) When Administered to Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age.
Status: Enrolling
Updated: 11/10/2015
Clinical Research Facility
mi
from
Scranton, PA
Click here to add this to my saved trials
Study of Menactra® in Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age
An Immunogenicity and Safety Evaluation of Menactra® (Meningococcal [Groups A, C, Y and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine) When Administered to Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age.
Status: Enrolling
Updated:  11/10/2015
Clinical Research Facility
mi
from
Sellersville, PA
Study of Menactra® in Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age
An Immunogenicity and Safety Evaluation of Menactra® (Meningococcal [Groups A, C, Y and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine) When Administered to Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age.
Status: Enrolling
Updated: 11/10/2015
Clinical Research Facility
mi
from
Sellersville, PA
Click here to add this to my saved trials
Study of Menactra® in Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age
An Immunogenicity and Safety Evaluation of Menactra® (Meningococcal [Groups A, C, Y and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine) When Administered to Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age.
Status: Enrolling
Updated:  11/10/2015
Clinical Research Facility
mi
from
Jackson, TN
Study of Menactra® in Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age
An Immunogenicity and Safety Evaluation of Menactra® (Meningococcal [Groups A, C, Y and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine) When Administered to Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age.
Status: Enrolling
Updated: 11/10/2015
Clinical Research Facility
mi
from
Jackson, TN
Click here to add this to my saved trials
Study of Menactra® in Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age
An Immunogenicity and Safety Evaluation of Menactra® (Meningococcal [Groups A, C, Y and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine) When Administered to Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age.
Status: Enrolling
Updated:  11/10/2015
Clinical Research Facility
mi
from
Kingsport, TN
Study of Menactra® in Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age
An Immunogenicity and Safety Evaluation of Menactra® (Meningococcal [Groups A, C, Y and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine) When Administered to Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age.
Status: Enrolling
Updated: 11/10/2015
Clinical Research Facility
mi
from
Kingsport, TN
Click here to add this to my saved trials
Study of Menactra® in Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age
An Immunogenicity and Safety Evaluation of Menactra® (Meningococcal [Groups A, C, Y and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine) When Administered to Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age.
Status: Enrolling
Updated:  11/10/2015
Clinical Research Facility
mi
from
Austin, TX
Study of Menactra® in Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age
An Immunogenicity and Safety Evaluation of Menactra® (Meningococcal [Groups A, C, Y and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine) When Administered to Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age.
Status: Enrolling
Updated: 11/10/2015
Clinical Research Facility
mi
from
Austin, TX
Click here to add this to my saved trials
Study of Menactra® in Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age
An Immunogenicity and Safety Evaluation of Menactra® (Meningococcal [Groups A, C, Y and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine) When Administered to Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age.
Status: Enrolling
Updated:  11/10/2015
Clinical Research Facility
mi
from
Fort Worth, TX
Study of Menactra® in Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age
An Immunogenicity and Safety Evaluation of Menactra® (Meningococcal [Groups A, C, Y and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine) When Administered to Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age.
Status: Enrolling
Updated: 11/10/2015
Clinical Research Facility
mi
from
Fort Worth, TX
Click here to add this to my saved trials
Study of Menactra® in Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age
An Immunogenicity and Safety Evaluation of Menactra® (Meningococcal [Groups A, C, Y and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine) When Administered to Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age.
Status: Enrolling
Updated:  11/10/2015
Clinical Research Facility
mi
from
Houston, TX
Study of Menactra® in Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age
An Immunogenicity and Safety Evaluation of Menactra® (Meningococcal [Groups A, C, Y and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine) When Administered to Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age.
Status: Enrolling
Updated: 11/10/2015
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
Study of Menactra® in Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age
An Immunogenicity and Safety Evaluation of Menactra® (Meningococcal [Groups A, C, Y and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine) When Administered to Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age.
Status: Enrolling
Updated:  11/10/2015
Clinical Research Facility
mi
from
Hurst, TX
Study of Menactra® in Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age
An Immunogenicity and Safety Evaluation of Menactra® (Meningococcal [Groups A, C, Y and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine) When Administered to Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age.
Status: Enrolling
Updated: 11/10/2015
Clinical Research Facility
mi
from
Hurst, TX
Click here to add this to my saved trials
Study of Menactra® in Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age
An Immunogenicity and Safety Evaluation of Menactra® (Meningococcal [Groups A, C, Y and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine) When Administered to Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age.
Status: Enrolling
Updated:  11/10/2015
Clinical Research Facility
mi
from
San Antonio, TX
Study of Menactra® in Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age
An Immunogenicity and Safety Evaluation of Menactra® (Meningococcal [Groups A, C, Y and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine) When Administered to Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age.
Status: Enrolling
Updated: 11/10/2015
Clinical Research Facility
mi
from
San Antonio, TX
Click here to add this to my saved trials
Study of Menactra® in Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age
An Immunogenicity and Safety Evaluation of Menactra® (Meningococcal [Groups A, C, Y and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine) When Administered to Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age.
Status: Enrolling
Updated:  11/10/2015
Clinical Research Facility
mi
from
Layton, UT
Study of Menactra® in Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age
An Immunogenicity and Safety Evaluation of Menactra® (Meningococcal [Groups A, C, Y and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine) When Administered to Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age.
Status: Enrolling
Updated: 11/10/2015
Clinical Research Facility
mi
from
Layton, UT
Click here to add this to my saved trials
Study of Menactra® in Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age
An Immunogenicity and Safety Evaluation of Menactra® (Meningococcal [Groups A, C, Y and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine) When Administered to Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age.
Status: Enrolling
Updated:  11/10/2015
Clinical Research Facility
mi
from
Murray, UT
Study of Menactra® in Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age
An Immunogenicity and Safety Evaluation of Menactra® (Meningococcal [Groups A, C, Y and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine) When Administered to Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age.
Status: Enrolling
Updated: 11/10/2015
Clinical Research Facility
mi
from
Murray, UT
Click here to add this to my saved trials
Study of Menactra® in Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age
An Immunogenicity and Safety Evaluation of Menactra® (Meningococcal [Groups A, C, Y and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine) When Administered to Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age.
Status: Enrolling
Updated:  11/10/2015
Clinical Research Facility
mi
from
Orem, UT
Study of Menactra® in Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age
An Immunogenicity and Safety Evaluation of Menactra® (Meningococcal [Groups A, C, Y and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine) When Administered to Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age.
Status: Enrolling
Updated: 11/10/2015
Clinical Research Facility
mi
from
Orem, UT
Click here to add this to my saved trials
Study of Menactra® in Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age
An Immunogenicity and Safety Evaluation of Menactra® (Meningococcal [Groups A, C, Y and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine) When Administered to Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age.
Status: Enrolling
Updated:  11/10/2015
Clinical Research Facility
mi
from
Payson, UT
Study of Menactra® in Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age
An Immunogenicity and Safety Evaluation of Menactra® (Meningococcal [Groups A, C, Y and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine) When Administered to Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age.
Status: Enrolling
Updated: 11/10/2015
Clinical Research Facility
mi
from
Payson, UT
Click here to add this to my saved trials
Study of Menactra® in Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age
An Immunogenicity and Safety Evaluation of Menactra® (Meningococcal [Groups A, C, Y and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine) When Administered to Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age.
Status: Enrolling
Updated:  11/10/2015
Clinical Research Facility
mi
from
Roy, UT
Study of Menactra® in Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age
An Immunogenicity and Safety Evaluation of Menactra® (Meningococcal [Groups A, C, Y and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine) When Administered to Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age.
Status: Enrolling
Updated: 11/10/2015
Clinical Research Facility
mi
from
Roy, UT
Click here to add this to my saved trials
Study of Menactra® in Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age
An Immunogenicity and Safety Evaluation of Menactra® (Meningococcal [Groups A, C, Y and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine) When Administered to Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age.
Status: Enrolling
Updated:  11/10/2015
Clinical Research Facility
mi
from
Spanish Fork, UT
Study of Menactra® in Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age
An Immunogenicity and Safety Evaluation of Menactra® (Meningococcal [Groups A, C, Y and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine) When Administered to Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age.
Status: Enrolling
Updated: 11/10/2015
Clinical Research Facility
mi
from
Spanish Fork, UT
Click here to add this to my saved trials
Study of Menactra® in Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age
An Immunogenicity and Safety Evaluation of Menactra® (Meningococcal [Groups A, C, Y and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine) When Administered to Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age.
Status: Enrolling
Updated:  11/10/2015
Clinical Research Facility
mi
from
Syracuse, UT
Study of Menactra® in Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age
An Immunogenicity and Safety Evaluation of Menactra® (Meningococcal [Groups A, C, Y and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine) When Administered to Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age.
Status: Enrolling
Updated: 11/10/2015
Clinical Research Facility
mi
from
Syracuse, UT
Click here to add this to my saved trials
Study of Menactra® in Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age
An Immunogenicity and Safety Evaluation of Menactra® (Meningococcal [Groups A, C, Y and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine) When Administered to Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age.
Status: Enrolling
Updated:  11/10/2015
Clinical Research Facility
mi
from
Midlothian, VA
Study of Menactra® in Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age
An Immunogenicity and Safety Evaluation of Menactra® (Meningococcal [Groups A, C, Y and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine) When Administered to Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age.
Status: Enrolling
Updated: 11/10/2015
Clinical Research Facility
mi
from
Midlothian, VA
Click here to add this to my saved trials
Study of Menactra® in Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age
An Immunogenicity and Safety Evaluation of Menactra® (Meningococcal [Groups A, C, Y and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine) When Administered to Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age.
Status: Enrolling
Updated:  11/10/2015
Clinical Research Facility
mi
from
Spokane, WA
Study of Menactra® in Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age
An Immunogenicity and Safety Evaluation of Menactra® (Meningococcal [Groups A, C, Y and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine) When Administered to Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age.
Status: Enrolling
Updated: 11/10/2015
Clinical Research Facility
mi
from
Spokane, WA
Click here to add this to my saved trials
Study of Menactra® in Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age
An Immunogenicity and Safety Evaluation of Menactra® (Meningococcal [Groups A, C, Y and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine) When Administered to Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age.
Status: Enrolling
Updated:  11/10/2015
mi
from
Ponce,
Study of Menactra® in Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age
An Immunogenicity and Safety Evaluation of Menactra® (Meningococcal [Groups A, C, Y and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine) When Administered to Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age.
Status: Enrolling
Updated: 11/10/2015
mi
from
Ponce,
Click here to add this to my saved trials
Infectivity, Replication & Immunogenicity of Live nH1N1 Vaccine
Evaluation of the Infectivity, Replication, and Immunogenicity of Live, Attenuated A/California/07/09 (nH1N1) Influenza Vaccine in Serosusceptible Adults
Status: Enrolling
Updated:  11/17/2015
Vaccine Research Unit Room 3-5000
mi
from
Rochester, NY
Infectivity, Replication & Immunogenicity of Live nH1N1 Vaccine
Evaluation of the Infectivity, Replication, and Immunogenicity of Live, Attenuated A/California/07/09 (nH1N1) Influenza Vaccine in Serosusceptible Adults
Status: Enrolling
Updated: 11/17/2015
Vaccine Research Unit Room 3-5000
mi
from
Rochester, NY
Click here to add this to my saved trials
Safety and Immunogenicity of the 2015-2016 Formulation of Fluzone® Quadrivalent (Influenza Vaccine) Among Healthy Children
Safety and Immunogenicity of the 2015-2016 Formulation of Fluzone® Quadrivalent (Influenza Vaccine) Among Healthy Children
Status: Enrolling
Updated:  12/7/2015
Clinical Research Facility
mi
from
Bardstown, KY
Safety and Immunogenicity of the 2015-2016 Formulation of Fluzone® Quadrivalent (Influenza Vaccine) Among Healthy Children
Safety and Immunogenicity of the 2015-2016 Formulation of Fluzone® Quadrivalent (Influenza Vaccine) Among Healthy Children
Status: Enrolling
Updated: 12/7/2015
Clinical Research Facility
mi
from
Bardstown, KY
Click here to add this to my saved trials
Safety and Immunogenicity of the 2015-2016 Formulation of Fluzone® Quadrivalent (Influenza Vaccine) Among Healthy Children
Safety and Immunogenicity of the 2015-2016 Formulation of Fluzone® Quadrivalent (Influenza Vaccine) Among Healthy Children
Status: Enrolling
Updated:  12/7/2015
Clinical Research Facility
mi
from
Salt Lake City, UT
Safety and Immunogenicity of the 2015-2016 Formulation of Fluzone® Quadrivalent (Influenza Vaccine) Among Healthy Children
Safety and Immunogenicity of the 2015-2016 Formulation of Fluzone® Quadrivalent (Influenza Vaccine) Among Healthy Children
Status: Enrolling
Updated: 12/7/2015
Clinical Research Facility
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Safety and Efficacy of Investigational Anti-Influenza Immune Plasma in Treating Influenza
A Randomized, Open-Label, Phase 2, Multicenter Safety and Exploratory Efficacy Study of Investigational Anti-Influenza Immune Plasma for the Treatment of Influenza (IRC002)
Status: Enrolling
Updated:  12/14/2015
David Geffen School of Medicine, UCLA
mi
from
Los Angeles, CA
Safety and Efficacy of Investigational Anti-Influenza Immune Plasma in Treating Influenza
A Randomized, Open-Label, Phase 2, Multicenter Safety and Exploratory Efficacy Study of Investigational Anti-Influenza Immune Plasma for the Treatment of Influenza (IRC002)
Status: Enrolling
Updated: 12/14/2015
David Geffen School of Medicine, UCLA
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Safety and Efficacy of Investigational Anti-Influenza Immune Plasma in Treating Influenza
A Randomized, Open-Label, Phase 2, Multicenter Safety and Exploratory Efficacy Study of Investigational Anti-Influenza Immune Plasma for the Treatment of Influenza (IRC002)
Status: Enrolling
Updated:  12/14/2015
Naval Medical Center - San Diego
mi
from
San Diego, CA
Safety and Efficacy of Investigational Anti-Influenza Immune Plasma in Treating Influenza
A Randomized, Open-Label, Phase 2, Multicenter Safety and Exploratory Efficacy Study of Investigational Anti-Influenza Immune Plasma for the Treatment of Influenza (IRC002)
Status: Enrolling
Updated: 12/14/2015
Naval Medical Center - San Diego
mi
from
San Diego, CA
Click here to add this to my saved trials
Safety and Efficacy of Investigational Anti-Influenza Immune Plasma in Treating Influenza
A Randomized, Open-Label, Phase 2, Multicenter Safety and Exploratory Efficacy Study of Investigational Anti-Influenza Immune Plasma for the Treatment of Influenza (IRC002)
Status: Enrolling
Updated:  12/14/2015
Los Angeles Biomedical Research Institute, CA
mi
from
Torrance, CA
Safety and Efficacy of Investigational Anti-Influenza Immune Plasma in Treating Influenza
A Randomized, Open-Label, Phase 2, Multicenter Safety and Exploratory Efficacy Study of Investigational Anti-Influenza Immune Plasma for the Treatment of Influenza (IRC002)
Status: Enrolling
Updated: 12/14/2015
Los Angeles Biomedical Research Institute, CA
mi
from
Torrance, CA
Click here to add this to my saved trials
Safety and Efficacy of Investigational Anti-Influenza Immune Plasma in Treating Influenza
A Randomized, Open-Label, Phase 2, Multicenter Safety and Exploratory Efficacy Study of Investigational Anti-Influenza Immune Plasma for the Treatment of Influenza (IRC002)
Status: Enrolling
Updated:  12/14/2015
Childrens National Medical Center
mi
from
Washington,
Safety and Efficacy of Investigational Anti-Influenza Immune Plasma in Treating Influenza
A Randomized, Open-Label, Phase 2, Multicenter Safety and Exploratory Efficacy Study of Investigational Anti-Influenza Immune Plasma for the Treatment of Influenza (IRC002)
Status: Enrolling
Updated: 12/14/2015
Childrens National Medical Center
mi
from
Washington,
Click here to add this to my saved trials
Safety and Efficacy of Investigational Anti-Influenza Immune Plasma in Treating Influenza
A Randomized, Open-Label, Phase 2, Multicenter Safety and Exploratory Efficacy Study of Investigational Anti-Influenza Immune Plasma for the Treatment of Influenza (IRC002)
Status: Enrolling
Updated:  12/14/2015
Washington DC VA Medical Center
mi
from
Washington,
Safety and Efficacy of Investigational Anti-Influenza Immune Plasma in Treating Influenza
A Randomized, Open-Label, Phase 2, Multicenter Safety and Exploratory Efficacy Study of Investigational Anti-Influenza Immune Plasma for the Treatment of Influenza (IRC002)
Status: Enrolling
Updated: 12/14/2015
Washington DC VA Medical Center
mi
from
Washington,
Click here to add this to my saved trials
Safety and Efficacy of Investigational Anti-Influenza Immune Plasma in Treating Influenza
A Randomized, Open-Label, Phase 2, Multicenter Safety and Exploratory Efficacy Study of Investigational Anti-Influenza Immune Plasma for the Treatment of Influenza (IRC002)
Status: Enrolling
Updated:  12/14/2015
University of Florida
mi
from
Gainesville, FL
Safety and Efficacy of Investigational Anti-Influenza Immune Plasma in Treating Influenza
A Randomized, Open-Label, Phase 2, Multicenter Safety and Exploratory Efficacy Study of Investigational Anti-Influenza Immune Plasma for the Treatment of Influenza (IRC002)
Status: Enrolling
Updated: 12/14/2015
University of Florida
mi
from
Gainesville, FL
Click here to add this to my saved trials
Safety and Efficacy of Investigational Anti-Influenza Immune Plasma in Treating Influenza
A Randomized, Open-Label, Phase 2, Multicenter Safety and Exploratory Efficacy Study of Investigational Anti-Influenza Immune Plasma for the Treatment of Influenza (IRC002)
Status: Enrolling
Updated:  12/14/2015
Emory University Hospital
mi
from
Atlanta, GA
Safety and Efficacy of Investigational Anti-Influenza Immune Plasma in Treating Influenza
A Randomized, Open-Label, Phase 2, Multicenter Safety and Exploratory Efficacy Study of Investigational Anti-Influenza Immune Plasma for the Treatment of Influenza (IRC002)
Status: Enrolling
Updated: 12/14/2015
Emory University Hospital
mi
from
Atlanta, GA
Click here to add this to my saved trials
Safety and Efficacy of Investigational Anti-Influenza Immune Plasma in Treating Influenza
A Randomized, Open-Label, Phase 2, Multicenter Safety and Exploratory Efficacy Study of Investigational Anti-Influenza Immune Plasma for the Treatment of Influenza (IRC002)
Status: Enrolling
Updated:  12/14/2015
Northwestern University (NU)
mi
from
Chicago, IL
Safety and Efficacy of Investigational Anti-Influenza Immune Plasma in Treating Influenza
A Randomized, Open-Label, Phase 2, Multicenter Safety and Exploratory Efficacy Study of Investigational Anti-Influenza Immune Plasma for the Treatment of Influenza (IRC002)
Status: Enrolling
Updated: 12/14/2015
Northwestern University (NU)
mi
from
Chicago, IL
Click here to add this to my saved trials
Safety and Efficacy of Investigational Anti-Influenza Immune Plasma in Treating Influenza
A Randomized, Open-Label, Phase 2, Multicenter Safety and Exploratory Efficacy Study of Investigational Anti-Influenza Immune Plasma for the Treatment of Influenza (IRC002)
Status: Enrolling
Updated:  12/14/2015
Rush University Medical Center
mi
from
Chicago, IL
Safety and Efficacy of Investigational Anti-Influenza Immune Plasma in Treating Influenza
A Randomized, Open-Label, Phase 2, Multicenter Safety and Exploratory Efficacy Study of Investigational Anti-Influenza Immune Plasma for the Treatment of Influenza (IRC002)
Status: Enrolling
Updated: 12/14/2015
Rush University Medical Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Safety and Efficacy of Investigational Anti-Influenza Immune Plasma in Treating Influenza
A Randomized, Open-Label, Phase 2, Multicenter Safety and Exploratory Efficacy Study of Investigational Anti-Influenza Immune Plasma for the Treatment of Influenza (IRC002)
Status: Enrolling
Updated:  12/14/2015
John Hopkins University (JHU)
mi
from
Baltimore, MD
Safety and Efficacy of Investigational Anti-Influenza Immune Plasma in Treating Influenza
A Randomized, Open-Label, Phase 2, Multicenter Safety and Exploratory Efficacy Study of Investigational Anti-Influenza Immune Plasma for the Treatment of Influenza (IRC002)
Status: Enrolling
Updated: 12/14/2015
John Hopkins University (JHU)
mi
from
Baltimore, MD
Click here to add this to my saved trials
Safety and Efficacy of Investigational Anti-Influenza Immune Plasma in Treating Influenza
A Randomized, Open-Label, Phase 2, Multicenter Safety and Exploratory Efficacy Study of Investigational Anti-Influenza Immune Plasma for the Treatment of Influenza (IRC002)
Status: Enrolling
Updated:  12/14/2015
University of Maryland School of Medicine Center for Vaccine Development
mi
from
Baltimore, MD
Safety and Efficacy of Investigational Anti-Influenza Immune Plasma in Treating Influenza
A Randomized, Open-Label, Phase 2, Multicenter Safety and Exploratory Efficacy Study of Investigational Anti-Influenza Immune Plasma for the Treatment of Influenza (IRC002)
Status: Enrolling
Updated: 12/14/2015
University of Maryland School of Medicine Center for Vaccine Development
mi
from
Baltimore, MD
Click here to add this to my saved trials
Safety and Efficacy of Investigational Anti-Influenza Immune Plasma in Treating Influenza
A Randomized, Open-Label, Phase 2, Multicenter Safety and Exploratory Efficacy Study of Investigational Anti-Influenza Immune Plasma for the Treatment of Influenza (IRC002)
Status: Enrolling
Updated:  12/14/2015
Walter Reed National Military Medical Center (WRNMMC)
mi
from
Bethesda, MD
Safety and Efficacy of Investigational Anti-Influenza Immune Plasma in Treating Influenza
A Randomized, Open-Label, Phase 2, Multicenter Safety and Exploratory Efficacy Study of Investigational Anti-Influenza Immune Plasma for the Treatment of Influenza (IRC002)
Status: Enrolling
Updated: 12/14/2015
Walter Reed National Military Medical Center (WRNMMC)
mi
from
Bethesda, MD
Click here to add this to my saved trials
Safety and Efficacy of Investigational Anti-Influenza Immune Plasma in Treating Influenza
A Randomized, Open-Label, Phase 2, Multicenter Safety and Exploratory Efficacy Study of Investigational Anti-Influenza Immune Plasma for the Treatment of Influenza (IRC002)
Status: Enrolling
Updated:  12/14/2015
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Safety and Efficacy of Investigational Anti-Influenza Immune Plasma in Treating Influenza
A Randomized, Open-Label, Phase 2, Multicenter Safety and Exploratory Efficacy Study of Investigational Anti-Influenza Immune Plasma for the Treatment of Influenza (IRC002)
Status: Enrolling
Updated: 12/14/2015
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
Safety and Efficacy of Investigational Anti-Influenza Immune Plasma in Treating Influenza
A Randomized, Open-Label, Phase 2, Multicenter Safety and Exploratory Efficacy Study of Investigational Anti-Influenza Immune Plasma for the Treatment of Influenza (IRC002)
Status: Enrolling
Updated:  12/14/2015
Brigham and Women's Hosp
mi
from
Boston, MA
Safety and Efficacy of Investigational Anti-Influenza Immune Plasma in Treating Influenza
A Randomized, Open-Label, Phase 2, Multicenter Safety and Exploratory Efficacy Study of Investigational Anti-Influenza Immune Plasma for the Treatment of Influenza (IRC002)
Status: Enrolling
Updated: 12/14/2015
Brigham and Women's Hosp
mi
from
Boston, MA
Click here to add this to my saved trials
Safety and Efficacy of Investigational Anti-Influenza Immune Plasma in Treating Influenza
A Randomized, Open-Label, Phase 2, Multicenter Safety and Exploratory Efficacy Study of Investigational Anti-Influenza Immune Plasma for the Treatment of Influenza (IRC002)
Status: Enrolling
Updated:  12/14/2015
Brigham and Women's Hospital/Harvard Medical School
mi
from
Boston, MA
Safety and Efficacy of Investigational Anti-Influenza Immune Plasma in Treating Influenza
A Randomized, Open-Label, Phase 2, Multicenter Safety and Exploratory Efficacy Study of Investigational Anti-Influenza Immune Plasma for the Treatment of Influenza (IRC002)
Status: Enrolling
Updated: 12/14/2015
Brigham and Women's Hospital/Harvard Medical School
mi
from
Boston, MA
Click here to add this to my saved trials
Safety and Efficacy of Investigational Anti-Influenza Immune Plasma in Treating Influenza
A Randomized, Open-Label, Phase 2, Multicenter Safety and Exploratory Efficacy Study of Investigational Anti-Influenza Immune Plasma for the Treatment of Influenza (IRC002)
Status: Enrolling
Updated:  12/14/2015
Massachusetts General Hospital
mi
from
Boston, MA
Safety and Efficacy of Investigational Anti-Influenza Immune Plasma in Treating Influenza
A Randomized, Open-Label, Phase 2, Multicenter Safety and Exploratory Efficacy Study of Investigational Anti-Influenza Immune Plasma for the Treatment of Influenza (IRC002)
Status: Enrolling
Updated: 12/14/2015
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Safety and Efficacy of Investigational Anti-Influenza Immune Plasma in Treating Influenza
A Randomized, Open-Label, Phase 2, Multicenter Safety and Exploratory Efficacy Study of Investigational Anti-Influenza Immune Plasma for the Treatment of Influenza (IRC002)
Status: Enrolling
Updated:  12/14/2015
Univ of Massachusetts Med School
mi
from
Worcester, MA
Safety and Efficacy of Investigational Anti-Influenza Immune Plasma in Treating Influenza
A Randomized, Open-Label, Phase 2, Multicenter Safety and Exploratory Efficacy Study of Investigational Anti-Influenza Immune Plasma for the Treatment of Influenza (IRC002)
Status: Enrolling
Updated: 12/14/2015
Univ of Massachusetts Med School
mi
from
Worcester, MA
Click here to add this to my saved trials
Safety and Efficacy of Investigational Anti-Influenza Immune Plasma in Treating Influenza
A Randomized, Open-Label, Phase 2, Multicenter Safety and Exploratory Efficacy Study of Investigational Anti-Influenza Immune Plasma for the Treatment of Influenza (IRC002)
Status: Enrolling
Updated:  12/14/2015
University of Michigan
mi
from
Ann Arbor, MI
Safety and Efficacy of Investigational Anti-Influenza Immune Plasma in Treating Influenza
A Randomized, Open-Label, Phase 2, Multicenter Safety and Exploratory Efficacy Study of Investigational Anti-Influenza Immune Plasma for the Treatment of Influenza (IRC002)
Status: Enrolling
Updated: 12/14/2015
University of Michigan
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Safety and Efficacy of Investigational Anti-Influenza Immune Plasma in Treating Influenza
A Randomized, Open-Label, Phase 2, Multicenter Safety and Exploratory Efficacy Study of Investigational Anti-Influenza Immune Plasma for the Treatment of Influenza (IRC002)
Status: Enrolling
Updated:  12/14/2015
Bronson Healthcare Group
mi
from
Kalamazoo, MI
Safety and Efficacy of Investigational Anti-Influenza Immune Plasma in Treating Influenza
A Randomized, Open-Label, Phase 2, Multicenter Safety and Exploratory Efficacy Study of Investigational Anti-Influenza Immune Plasma for the Treatment of Influenza (IRC002)
Status: Enrolling
Updated: 12/14/2015
Bronson Healthcare Group
mi
from
Kalamazoo, MI
Click here to add this to my saved trials
Safety and Efficacy of Investigational Anti-Influenza Immune Plasma in Treating Influenza
A Randomized, Open-Label, Phase 2, Multicenter Safety and Exploratory Efficacy Study of Investigational Anti-Influenza Immune Plasma for the Treatment of Influenza (IRC002)
Status: Enrolling
Updated:  12/14/2015
Saint Mary's Hospital (Mayo Clinic)
mi
from
Rochester, MN
Safety and Efficacy of Investigational Anti-Influenza Immune Plasma in Treating Influenza
A Randomized, Open-Label, Phase 2, Multicenter Safety and Exploratory Efficacy Study of Investigational Anti-Influenza Immune Plasma for the Treatment of Influenza (IRC002)
Status: Enrolling
Updated: 12/14/2015
Saint Mary's Hospital (Mayo Clinic)
mi
from
Rochester, MN
Click here to add this to my saved trials
Safety and Efficacy of Investigational Anti-Influenza Immune Plasma in Treating Influenza
A Randomized, Open-Label, Phase 2, Multicenter Safety and Exploratory Efficacy Study of Investigational Anti-Influenza Immune Plasma for the Treatment of Influenza (IRC002)
Status: Enrolling
Updated:  12/14/2015
Cornell Clinical Trials Unit, New York Presbyterian Hospital, Weill Cornell Medical College
mi
from
New York, NY
Safety and Efficacy of Investigational Anti-Influenza Immune Plasma in Treating Influenza
A Randomized, Open-Label, Phase 2, Multicenter Safety and Exploratory Efficacy Study of Investigational Anti-Influenza Immune Plasma for the Treatment of Influenza (IRC002)
Status: Enrolling
Updated: 12/14/2015
Cornell Clinical Trials Unit, New York Presbyterian Hospital, Weill Cornell Medical College
mi
from
New York, NY
Click here to add this to my saved trials
Safety and Efficacy of Investigational Anti-Influenza Immune Plasma in Treating Influenza
A Randomized, Open-Label, Phase 2, Multicenter Safety and Exploratory Efficacy Study of Investigational Anti-Influenza Immune Plasma for the Treatment of Influenza (IRC002)
Status: Enrolling
Updated:  12/14/2015
Montefiore Medical Center/Albert Einstein College of Medicine
mi
from
New York, NY
Safety and Efficacy of Investigational Anti-Influenza Immune Plasma in Treating Influenza
A Randomized, Open-Label, Phase 2, Multicenter Safety and Exploratory Efficacy Study of Investigational Anti-Influenza Immune Plasma for the Treatment of Influenza (IRC002)
Status: Enrolling
Updated: 12/14/2015
Montefiore Medical Center/Albert Einstein College of Medicine
mi
from
New York, NY
Click here to add this to my saved trials
Safety and Efficacy of Investigational Anti-Influenza Immune Plasma in Treating Influenza
A Randomized, Open-Label, Phase 2, Multicenter Safety and Exploratory Efficacy Study of Investigational Anti-Influenza Immune Plasma for the Treatment of Influenza (IRC002)
Status: Enrolling
Updated:  12/14/2015
Mount Sinai Hospital
mi
from
New York, NY
Safety and Efficacy of Investigational Anti-Influenza Immune Plasma in Treating Influenza
A Randomized, Open-Label, Phase 2, Multicenter Safety and Exploratory Efficacy Study of Investigational Anti-Influenza Immune Plasma for the Treatment of Influenza (IRC002)
Status: Enrolling
Updated: 12/14/2015
Mount Sinai Hospital
mi
from
New York, NY
Click here to add this to my saved trials
Safety and Efficacy of Investigational Anti-Influenza Immune Plasma in Treating Influenza
A Randomized, Open-Label, Phase 2, Multicenter Safety and Exploratory Efficacy Study of Investigational Anti-Influenza Immune Plasma for the Treatment of Influenza (IRC002)
Status: Enrolling
Updated:  12/14/2015
University of North Carolina at Chapel Hill
mi
from
Chapel Hill, NC
Safety and Efficacy of Investigational Anti-Influenza Immune Plasma in Treating Influenza
A Randomized, Open-Label, Phase 2, Multicenter Safety and Exploratory Efficacy Study of Investigational Anti-Influenza Immune Plasma for the Treatment of Influenza (IRC002)
Status: Enrolling
Updated: 12/14/2015
University of North Carolina at Chapel Hill
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Safety and Efficacy of Investigational Anti-Influenza Immune Plasma in Treating Influenza
A Randomized, Open-Label, Phase 2, Multicenter Safety and Exploratory Efficacy Study of Investigational Anti-Influenza Immune Plasma for the Treatment of Influenza (IRC002)
Status: Enrolling
Updated:  12/14/2015
University of Cincinnati College of Medicine
mi
from
Cincinnati, OH
Safety and Efficacy of Investigational Anti-Influenza Immune Plasma in Treating Influenza
A Randomized, Open-Label, Phase 2, Multicenter Safety and Exploratory Efficacy Study of Investigational Anti-Influenza Immune Plasma for the Treatment of Influenza (IRC002)
Status: Enrolling
Updated: 12/14/2015
University of Cincinnati College of Medicine
mi
from
Cincinnati, OH
Click here to add this to my saved trials